Chemotherapy

Abraxane instead of Taxotere and carboplatin led to a better response and fewer serious side effects.

Chemotherapy ups the risk that older women with breast cancer will have difficulty walking or climbing stairs.

“The short-term fasting group didn’t even develop any clinically visible fatigue,” according to the study presenter.

Eating a healthy diet and exercising improved pathologic complete response rates in certain women receiving chemotherapy before surgery.

If you’re in treatment for breast cancer, you’re likely to benefit from extra COVID-19 boosters. How often you get them depends on the medicines you’re receiving.

Peripheral neuropathy is common in people receiving taxane chemotherapy for breast cancer and is more severe with Taxol.

Chemotherapy — instead of hormonal therapy — plus two anti-HER2 medicines before surgery offered better pCR rates.

Receiving anthracycline chemotherapy for breast cancer increases heart failure risk that lasts for many years.

Four more years of follow-up continue to show that women with an Oncotype DX Breast Recurrence Score of 11-25 can safely skip chemotherapy; their risk or recurrence wasn’t higher than women who received chemotherapy.

Women diagnosed with early-stage breast cancer receiving anthracycline chemotherapy who completed a 12-month exercise program had a lower risk of functional problems and better cardiovascular health.

People who started an exercise program during chemotherapy had less severe side effects and got back to regular physical functioning faster than people who started exercising after completing chemotherapy.

People’s age, the type of health insurance they had, where they lived, and the number of other health conditions they had were all factors in their refusal to receive chemotherapy to treat advanced-stage breast cancer.

Hand cooling and hand compression both worked well to reduce the risk of neuropathy in people receiving taxane chemotherapy for breast cancer.

Neurofeedback — a type of therapy that uses a computer program to measure brain wave activity — shows promise for treating the mental fogginess many people have after chemotherapy.

After receiving chemotherapy for breast cancer, women who had more severe, persistent fatigue were more likely to have balance problems, whether they had peripheral neuropathy or not.

Metastatic breast cancer responded better to a combination of the chemotherapy medicine paclitaxel in pill form and encequidar (a medicine that allows oral paclitaxel to be absorbed into the bloodstream) than to intravenous paclitaxel.

Hearing loss and other hearing problems seem to be common in adults who’ve received chemotherapy for the four most common types of cancer, including breast cancer.

Exercise helped reduce the risk of heart problems in women receiving treatment for breast cancer.

Among women who had breast cancer surgery and axillary lymph node dissection, Black and Hispanic women were more likely to develop lymphedema than white women, as were women who received chemotherapy before surgery, rather than after surgery.

Previous chemotherapy treatment, more belly fat, and being less physically fit led to a lower immune response to a typhoid vaccine in women who’d been treated for breast cancer.

Adding the immunotherapy medicine Keytruda to chemotherapy improved overall survival more than chemotherapy alone in people diagnosed with metastatic triple-negative, strongly PD-L1-positive breast cancer, according to the KEYNOTE-355 study’s final results.

Adding carboplatin (brand name: Paraplatin) to the standard neoadjuvant chemotherapy regimen for early-stage triple-negative breast cancer improved event-free survival.

Six months after receiving their second dose of the Pfizer COVID-19 vaccine, people diagnosed with solid tumor cancers had about the same antibody levels as people who hadn’t been diagnosed with cancer.

Women with a genetic mutation linked to a higher cancer risk who are diagnosed with breast cancer or ovarian cancer and receive chemotherapy treatment have the same or better survival rates as women who don’t have a genetic mutation linked to higher risk.